65% of eligible lung cancer patients do not receive the most appropriate targeted therapies, Diaceutics report finds
“The updated Clinical Practice Gaps report, based on real-world data from more than 35,800 newly diagnosed aNSCLC patients between 2019 and 2023, reveals that the largest loss of patients now occurs at the treatment decision stage, underscoring a critical disconnect between precision diagnostics and therapy selection.”
Rates of Systemic Treatment for Metastatic Non–Small Cell Lung Cancer Among Older Adults
“Conclusions and Relevance: In this cohort study of older adults with mNSCLC, despite advances in therapy in recent decades, almost half of patients never received systemic therapy, and the proportion treated only minimally improved over time. Approximately one-fifth of those with the most favorable clinical profiles did not receive systemic therapy.”
Zongertinib Delivers 76% Response Rate as a First-Line Therapy in HER2-Mutant NSCLC
“Key Takeaways: Selective HER2 inhibition with sparing of wild-type EGFR aims to mitigate rash and diarrhea seen with less selective pan-HER strategies. In cohort 2, 120 mg once daily yielded a 76% confirmed ORR (11% CR), with median DoR 15.2 months and PFS 14.4 months.”
Simple measurement from routine X-rays accurately predicts post-op lung cancer outcomes
“For the first time, research has identified diaphragmatic dome height measured on chest X-rays as an indicator of what patients’ post-op recovery will look like following surgery for cancer or other lung disorders. Dome height is indicative of diaphragmatic function, which is key for breathing. Lower height could signal poor function and, therefore, may allude to inefficient breathing after lung surgery, researchers proposed.”
Urine nanosensor tracks lung cancer signals and early fibrosis, moving toward clinical trials
“A urine test developed by scientists at the University of Cambridge has moved a step closer to clinical use following new findings revealing it could do more than first thought. Originally designed to detect early signs of lung cancer and treatment resistance, the test shows potential in identifying biological signals associated with pulmonary fibrosis—a serious condition where early diagnosis remains a major challenge.”
Incidence, Risk Factors, and Impact of Immunotherapy on Brain Metastasis in Extensive-Stage Small Cell Lung Cancer Without Baseline Brain Involvement
“Conclusion: Adding immunotherapy to chemotherapy did not significantly reduce brain metastasis incidence in ES-SCLC patients without baseline brain involvement. PCI remained the sole evidence-based strategy for brain metastasis prevention in this population, underscoring the need for novel CNS-directed approaches.”
Health behaviors and symptom clusters mediate self-management efficacy and quality of life in lung cancer immunotherapy
“Results suggest that patients with higher self-management efficacy demonstrate greater engagement in proactive health-promoting behaviors. These behaviors, in turn, appear to mitigate the negative impact of treatment-related symptom clusters, ultimately leading to improve quality of life.”
Redefining care for early-stage lung cancer with immunotherapy combo
“The KEYNOTE-671 trial has redefined the standard of care for the treatment of early-stage lung cancer by bringing powerful immunotherapies, previously used in advanced-stage cancer, into treatment for earlier stages. Stanford Cancer Institute Deputy Director Heather Wakelee, MD, the Winston Chen and Phyllis Huang Professor, led the steering committee for this trial, which focused on stage 2 and 3 non-small cell lung cancer (NSCLC). While technically removable by surgery, the cancer carries a high risk of returning after surgery. By treating the cancer with immunotherapy before and after surgery, a method known as the perioperative or sandwich approach, researchers are seeing improvements in long-term survival.”
Marijuana Use May Raise Lung Cancer Risk, Researchers Warn
“As marijuana becomes legal in more states, many people are asking whether it is actually safe. While the link between tobacco smoking and lung cancer is well established, the connection between marijuana use and cancer remains less clear, according to Brooks Udelsman, MD, a thoracic surgeon with USC Surgery, part of Keck Medicine of USC.”
Investigators Initiate Dosing in Phase 1b/2 Trial of SNB-101 in ES-SCLC
“Investigators have initiated dosing for the first patient enrolled on an international phase 1b/2 trial (NCT07391813) evaluating the investigational nanoparticle agent SNB-101 among patients with extensive-stage small cell lung cancer, according to a press release from the developer, SN Biosciences, Inc.”
U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer
“WHIPPANY, N.J., May 18, 2026 – Bayer announced today that the U.S. Food and Drug Administration (FDA) has granted HYRNUO® (sevabertinib) Priority Review status for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations in patients with no prior therapy. HYRNUO is not currently approved in this first-line setting.”
NBTXR3 Shows 57% Complete Response Rate in Stage III Lung Cancer Study
“A 57% complete response rate in stage III unresectable NSCLC stops you cold — the current standard of care, concurrent chemoradiation plus durvalumab, produces complete responses in fewer than 5% of patients. That is the number that frames everything about the Part 1 data from CONVERGE, a J&J-sponsored randomized Phase 2 study of JNJ-1900 (NBTXR3) presented at ESTRO 2026. Seven patients completed the full treatment regimen. Four achieved complete response. Six responded. All seven had disease control. The sample is tiny, but the directional signal is not subtle.”
